Semaglutide for Atrial Fibrillation

(SEMINAL-AF Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen by Silvana Pannain, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: University of Chicago

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 6 Jurisdictions

Trial Summary

What is the purpose of this trial?

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

Research Team

Silvana Pannain, MD

Principal Investigator

University of Chicago

Eligibility Criteria

This trial is for individuals with obesity and atrial fibrillation (AF), a type of irregular heartbeat. Participants should be seeking treatment for AF and are interested in how weight loss might affect their condition.

Inclusion Criteria

I am between 18 and 75 years old.

BMI greater than or equal to 30 kg/m2

I will follow a specific plan for adjusting my diabetes medication during the study.

Exclusion Criteria

I have not had a pulmonary embolism in the last 90 days.

Uncontrolled thyroid disease: TSH (Thyroid-stimulating hormone) > 10.0 mIU/L or < 0.4 mIU/L at screening

I have a history of type I diabetes.

Treatment Details

Interventions

• Semaglutide (Anti-obesity Agent)

Trial Overview The study is testing the effects of semaglutide, a medication used for weight loss, on patients with AF. It aims to see if this drug, alongside standard AF treatments, can reduce the severity of AF or prevent it from coming back.

Participant Groups

Group I: Semaglutide Active Control 1 Intervention

Participants will have a 2 in 3 chance of receiving semaglutide (2.4 mg).

Group II: Placebo Placebo Group 1 Intervention

Participants will have a 1 in 3 chance of receiving placebo.

Semaglutide is already approved in Canada, Japan for the following indications:

Approved in Canada as Ozempic for:

• Type 2 diabetes
• Cardiovascular disease
• Obesity

Approved in Japan as Ozempic for:

• Type 2 diabetes
• Cardiovascular disease
• Obesity

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

The University of Arizona College of Medicine- Phoenix Phoenix, AZ

University of Chicago Chicago, IL

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials

1086

Patients Recruited

844,000+